- Date of occurrence of the event: Jun 16, 2019
- Company name: OBI Pharma Inc.
- Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
- Reciprocal shareholding ratios: N/A
- Name of mass media: Page A10 of Economy Daily News on Jun 16, 2019
- Content reported: ……OBI to hold Annual General Meeting on the 27th……Antibody drug conjugate OBI-999 will enter clinical phase in the second half of the year.
- Cause of occurrence: Clarification on news article
- Countermeasures: United States FDA IND of antibody drug conjugate OBI-999 is planned for this year, please refer to Page 2 & Page 72 of the 2018 Annual Report.
Website: http://doc.twse.com.tw/server-java/t57sb01?step=1&colorchg=1&co_id=4174&year=108&mtype=F& - Any other matters that need to be specified: New drug development is a long process associated with high costs. It is not a achat de kamagra, which may increase the risk of investment. Investors shall make prudent judgments and investments.
